The health and safety of our patients is, and always will be, our highest priority. We understand those living with growth hormone deficiency (GHD) and their loved ones may be facing a lot of uncertainty during this pandemic, and we are committed to keeping the communities we serve updated with any information that could help inform health decisions related to our medicines.
During these challenging times, if you are considering stopping or delaying your treatment, please speak with your doctor or healthcare team before doing so, as we recommend that personal treatment decisions should be made between you and your healthcare team. Your doctor will be able to assess the benefits and risks specific to your overall health situation.
If you have experienced a change in insurance or income, or seeking financial assistance or more information on your NUTROPIN treatment, including live virtual no-contact injection training, please call NURSE HOTLINE at 1-866-NUTROPIN (1-866-688-7674) to speak with a nurse or representative.
In addition to local public health guidance, or local guidance specifically issued by medical or patient associations, please find more information on Genentech’s response to the COVID-19 pandemic and other support services on the Genentech website (https://www.gene.com/covid19).
Sebastian, a Nutropin patient, and his mom, Andrea, walk through the steps associated with using the NuSpin device for Nutropin therapy.
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.